AU2021373873A1 - Membrane protein targeting engineered deubiquitinases and methods of use thereof - Google Patents

Membrane protein targeting engineered deubiquitinases and methods of use thereof Download PDF

Info

Publication number
AU2021373873A1
AU2021373873A1 AU2021373873A AU2021373873A AU2021373873A1 AU 2021373873 A1 AU2021373873 A1 AU 2021373873A1 AU 2021373873 A AU2021373873 A AU 2021373873A AU 2021373873 A AU2021373873 A AU 2021373873A AU 2021373873 A1 AU2021373873 A1 AU 2021373873A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
disease
seq
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021373873A
Other languages
English (en)
Other versions
AU2021373873A9 (en
Inventor
Samuel W. HALL
Andreas Loew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flux Therapeutics Inc
Original Assignee
Flux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flux Therapeutics Inc filed Critical Flux Therapeutics Inc
Publication of AU2021373873A1 publication Critical patent/AU2021373873A1/en
Publication of AU2021373873A9 publication Critical patent/AU2021373873A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021373873A 2020-11-06 2021-11-05 Membrane protein targeting engineered deubiquitinases and methods of use thereof Pending AU2021373873A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110619P 2020-11-06 2020-11-06
US63/110,619 2020-11-06
PCT/US2021/058291 WO2022099038A1 (en) 2020-11-06 2021-11-05 Membrane protein targeting engineered deubiquitinases and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2021373873A1 true AU2021373873A1 (en) 2023-06-08
AU2021373873A9 AU2021373873A9 (en) 2024-08-01

Family

ID=81456825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021373873A Pending AU2021373873A1 (en) 2020-11-06 2021-11-05 Membrane protein targeting engineered deubiquitinases and methods of use thereof

Country Status (7)

Country Link
US (1) US20240002473A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240754A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023548973A (cg-RX-API-DMAC7.html)
CN (1) CN116802198A (cg-RX-API-DMAC7.html)
AU (1) AU2021373873A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200983A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022099038A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026085496A1 (en) * 2024-10-18 2026-04-23 The Trustees Of Columbia University In The City Of New York Compositions and methods for using engineered deubiquitinases for targeted stabilization of voltage-gated sodium channels
CN121471382B (zh) * 2026-01-12 2026-07-24 合肥综合性国家科学中心大健康研究院 去泛素化酶Fc融合蛋白及其产品、制备方法和在苗头化合物筛选中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541074A (en) * 1986-07-25 1996-07-30 The Children's Medical Center Corporation Antibodies to dystrophin and uses therefor
CN101671688A (zh) * 2009-09-25 2010-03-17 上海大学 EGFP融合的β2肾上腺素能受体、其重组表达载体及其构建方法
EP3706782A4 (en) * 2017-11-06 2021-09-08 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS OF USING MANIPULATED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELL PROCESSES
WO2019126762A2 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
EP3793689A1 (en) * 2018-05-15 2021-03-24 Translate Bio, Inc. Subcutaneous delivery of messenger rna

Also Published As

Publication number Publication date
WO2022099038A1 (en) 2022-05-12
CN116802198A (zh) 2023-09-22
CA3200983A1 (en) 2022-05-12
JP2023548973A (ja) 2023-11-21
EP4240754A1 (en) 2023-09-13
US20240002473A1 (en) 2024-01-04
EP4240754A4 (en) 2024-09-04
AU2021373873A9 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US20230382991A1 (en) Anti-lilrb antibodies and uses thereof
JP2025166089A (ja) 配列類似性19、メンバーa5抗体を有する抗ファミリー及びその使用方法
EP4143322A1 (en) Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use
TW202346354A (zh) 抗ceacam5抗體及其結合物及用途
US20240002473A1 (en) Membrane protein targeting engineered deubiquitinases and methods of use thereof
WO2018087143A2 (en) Anti-pd-1 antibodies
CN104204217A (zh) 抗cd20抗体利妥昔单抗的稳定化
US20240026329A1 (en) Nuclear protein targeting deubiquitinases and methods of use
CN117729938A (zh) 用于使用利用抗muc16×cd3多特异性抗体和vegf抑制剂的组合疗法治疗妇科癌症的方法
US20250188186A1 (en) Ph-selective antibody fc domains
CN107208315A (zh) 涉及嵌入异源蛋白质支架中的功能性多肽的方法和组合物
US20240026330A1 (en) Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof
CN103596984B (zh) 抗-人epo受体的抗体及使用方法
EP3262069B1 (en) Use of antibodies and antagonists directed against lrg1 in treatment
US20240025984A1 (en) Cytosolic protein targeting deubiquitinases and methods of use
EP4293046A1 (en) Anti-pd-1 antibody and use thereof
TW202513590A (zh) 與lilrb1結合的抗體或抗原結合片段及其用途
JP2023542497A (ja) 抗セルロプラスミン抗体及びその使用

Legal Events

Date Code Title Description
SREP Specification republished